VIVEX Biologics

VIVEX Biologics is a United States regenerative medicine company headquartered in Atlanta, Georgia, that develops, processes, stores and distributes human cells, tissues and cellular and tissue-based products (HCT/Ps) as well as medical devices to hospitals, medical professionals and approved distributors. Its stated mission is to provide advanced allografts that help patients suffering from musculoskeletal injuries, wounds and burned skin, and its purpose is framed around supporting the body's own regenerative potential. The company organizes its portfolio into three solution therapy areas. Interventional Pain Therapies focus on allogeneic disc tissue therapy for supplementing degenerated intervertebral discs. Wound Care & Amnion Therapies cover amniotic allografts used to support surgical wound treatment in neurosurgery, orthopedic and spine settings. Orthopedic & Fusion Therapies supply allografts used by surgeons to aid healing across spine, neurosurgery, foot and ankle, orthopedic oncology, podiatry, sports medicine and orthopedic/trauma specialties. These products serve patients with interventional pain, musculoskeletal injuries, chronic wounds, and burned or injured skin. VIVEX traces its medical technology lineage back 50 years to the founding of The University of Miami Tissue Bank in 1970, and describes multiple clinical and scientific firsts since that time. The company says it has distributed more than 2,000,000 allografts nationwide and that its products are used to help the lives of more than 100,000 patients annually. It emphasizes a proprietary manufacturing approach called Integrity Processing™, which it describes as protecting tissue from harmful cleaning agents and maintaining the natural state of tissue to preserve the inherent characteristics of allografts. Regulatory compliance is central to the business model. VIVEX states that it processes, stores and distributes HCT/Ps and distributes medical devices in compliance with FDA requirements, state regulations and American Association of Tissue Banks (AATB) standards. It reports zero documented cases of disease transmission across more than two million distributed allografts. The company has exclusively partnered with Legacy Donor Services Foundation, an AATB-accredited recovery service responsible for the recovery and care of tissue donations, along with other partners, to recover tissues aseptically. VIVEX is privately held and is expanding its Amnion & Wound Care Distribution Network, inviting potential distribution partners to join. Its leadership team includes Executive Chairman John A. McCallum, Co-Presidents Barry Salzman and Reinaldo (Rey) Pascual, Chief Technology Officer Timothy Ganey, Ph.D., and Chief Medical Officer H. Thomas Temple, MD, among other executives. The company operates Customer Experience and Research & Development Centers and presents itself as a leader in allograft research and development, advancing the field of bone and soft tissue transplantation.

VIVEX Biologics presents its medical technology heritage as dating back 50 years to the founding of The University of Miami Tissue Bank in 1970. From that origin, the company says it has experienced multiple firsts in clinical and scientific achievements, building a foundation in tissue banking and transplantation that it now applies to regenerative medicine. Over time, the organization evolved into a commercial developer and distributor of human tissue allografts. Its current portfolio is organized around three solution therapy areas: Interventional Pain Therapies, Wound Care & Amnion Therapies, and Orthopedic & Fusion Therapies. These products are used in specialties including spine, neurosurgery, foot and ankle, orthopedic oncology, podiatry, sports medicine, and orthopedic/trauma, and they address conditions such as low back pain, musculoskeletal injuries, chronic wounds, burned and injured skin, and aging and degenerative joints. A defining element of the company's history is its proprietary manufacturing methodology, Integrity Processing™. VIVEX describes this as an innovative processing approach focused on protecting tissue from harmful cleaning agents, maintaining the natural state of tissue, and preserving the inherent characteristics of allografts to support patients' regenerative potential. The company positions this methodology as a differentiator in allograft research and development. By the time of its current public communications, VIVEX reported that more than 2,000,000 allografts had been distributed nationwide, with its products used to help the lives of more than 100,000 patients annually. It also reported zero documented cases of disease transmission across that distribution history. The company states that it processes, stores and distributes HCT/Ps and distributes medical devices in compliance with FDA requirements, state regulations, and AATB standards. VIVEX has exclusively partnered with Legacy Donor Services Foundation, an AATB-accredited recovery service responsible for the recovery and care of tissue donations and for providing educational resources for would-be donors and their families, along with several other partners, to recover tissues aseptically in strict adherence to applicable standards. The company operates Customer Experience and Research & Development Centers and has been expanding its Amnion & Wound Care Distribution Network, seeking distribution partners. Its strategic plan is focused on developing new innovative allografts, research and development, enhancing manufacturing capabilities, and sales and marketing efforts.

• 2023

  Erin Chance becomes Chief Compliance Officer of VIVEX Biologics.

• 2019

  Erin Chance joins VIVEX Biologics as Assistant General Counsel.

• 1970

  The University of Miami Tissue Bank is founded, the origin VIVEX cites for its medical technologies.

Regenerative medicine company focused on innovative allografts, proprietary Integrity Processing™ manufacturing, FDA/AATB compliance and a nationwide distribution network.

• Interventional Pain Therapies

  Allogeneic disc tissue therapy for supplementing degenerated intervertebral discs.

• Wound Care & Amnion Therapies

  Amniotic allografts to support surgical wound treatment in neurosurgery, orthopedic and spine.

• Orthopedic & Fusion Therapies

  Allografts utilized by surgeons to aid with healing in spine, neurosurgery, foot & ankle, orthopedic oncology, podiatry, sports medicine, and orthopedic/trauma.

• Integrity Processing™

  Proprietary processing methodology focused on protecting tissue from harmful cleaning agents and maintaining the natural state of tissue.

1. 1VIVEX Biologics: The science of extraordinaryvivex.com
2. 2VIVEX Biologics: The science of extraordinaryvivex.com
3. 3VIVEX Biologics: The science of extraordinaryvivex.com
4. 4VIVEX Biologics: The science of extraordinaryvivex.com
5. 5Vivex Biologics (United States)wikidata.org
6. 6Vivex Biologics, Inc. Launches VIA Mend™ Synthetic Bone Fillersprnewswire.com